Funder
The University of Alberta funded open access publication of this article.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference98 articles.
1. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry Rev Can Psychiatry. 2016;61:510–23.
2. Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry Rev Can Psychiatry. 2016;61:524–39.
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
4. Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder. Can J Psychiatry. 2021;66:113–25.
5. Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato): (Janssen Inc.): Indication: Major Depressive Disorder in Adults [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2021 Apr. Appendix 1, Cost Comparison Table. https://www.ncbi.nlm.nih.gov/books/NBK572205/.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献